June 2, 2026

GLP-1 Insurance Coverage & Prior-Authorization Guide (2026): What's Covered and How to Get Approved

How GLP-1 coverage works in 2026: PBM formularies, prior-authorization rules, Medicare's $50 Bridge, Medicaid by state, savings cards, and appealing a denial.

Whether a GLP-1 drug is covered in 2026 depends less on the drug than on who is paying and why. The same Wegovy or Zepbound prescription can cost a $25 copay, a $349 cash payment, or nothing at all, depending on the plan, the diagnosis on the chart, and whether a prior authorization clears. Coverage also moved a lot this year: CVS Caremark dropped Zepbound and then reversed course, California's Medicaid program ended weight-loss coverage, Medicare opened a $50 bridge, and both manufacturers cut cash prices.

This guide maps the four pathways people actually use (commercial and employer plans through their pharmacy benefit managers, Medicare, Medicaid, and cash or manufacturer programs), plus the prior-authorization rules that decide approvals and the appeals process when a claim is denied. Every figure is dated and sourced; prices and formularies in this category change quarterly, so treat the dates as load-bearing.

For the Medicare program specifically, see the Medicare GLP-1 Bridge Pricing Guide. For list and cash prices across products, see GLP-1 Pricing: May 2026.

View pricing trends charts →

Commercial and employer plans: the PBM formulary

Most working-age people get GLP-1s through an employer plan administered by one of the three large pharmacy benefit managers (CVS Caremark, Express Scripts, OptumRx). Two things decide access: whether the employer bought obesity coverage at all, and whether the PBM keeps the specific drug on formulary. Both shifted in 2025–2026. CVS Caremark made Wegovy its preferred obesity GLP-1 and dropped Zepbound on July 1, 2025, then reversed after backlash and a class-action suit.

Channel	Price	Details	Source
CVS Caremark (standard commercial)	Wegovy preferred	Dropped Zepbound July 1, 2025; restoring it October 1, 2026 and adding Lilly's oral Foundayo June 1, 2026 after backlash	CNBC
Express Scripts / Cigna	Both covered (with PA)	Obesity coverage is an employer opt-in; the Patient Assurance Program caps eligible out-of-pocket cost at $200/month	Evernorth
Large employers (5,000+ workers) covering obesity GLP-1	43%	Up from 28% a year earlier; 16% of firms with 200–999 workers and 30% of those with 1,000–4,999 cover them (KFF 2025)	KFF 2025 Employer Survey
Covering firms that require a lifestyle program	34%	Share requiring enrollees to see a dietitian, case manager, or join a lifestyle program before coverage applies	KFF 2025 Employer Survey

Prior-authorization criteria: what plans require

When a commercial plan covers obesity GLP-1s, it almost always gates them behind prior authorization. The criteria are fairly consistent across payers: a BMI threshold, documented comorbidities, often a step-therapy trial of a cheaper agent, and a documented diet-and-exercise effort. Continued coverage usually depends on showing the drug is working.

Channel	Price	Details	Source
Initial PA: BMI threshold	≥30, or ≥27 + comorbidity	Qualifying comorbidities include type 2 diabetes, hypertension, high cholesterol, sleep apnea, and cardiovascular disease	SingleCare
Step therapy	Often required	A documented prior trial of a non-GLP-1 weight agent plus a low-calorie diet and increased activity, typically within the past 6 months	SingleCare
Reauthorization	≥5% weight loss	Most plans require documented loss of at least 5% of baseline body weight at about 6 months to keep covering the drug	SingleCare
Initial authorization duration (UnitedHealthcare)	5–6 months	Wegovy approvals run about 5 months and Zepbound about 6 months before renewal, contingent on documented response	UnitedHealthcare

Medicare: coverage by indication, plus the $50 Bridge

Medicare Part D cannot cover a drug used only for weight loss, a statutory exclusion dating to the 2003 law that created the benefit. But Part D does cover GLP-1s prescribed for an approved non-weight-loss indication, and a string of FDA approvals has widened that door. Separately, a temporary CMS demonstration provides weight-loss access at a flat $50 copay starting July 1, 2026.

Channel	Price	Details	Source
Part D: weight loss only	Not covered	Statutory exclusion under the 2003 Medicare Modernization Act	HHS ASPE
Part D: type 2 diabetes (Ozempic, Mounjaro)	Covered	Standard Part D cost-sharing applies, now under the IRA's ~$2,000 annual out-of-pocket cap	KFF
Part D: Wegovy for cardiovascular risk	Covered (by indication)	FDA approved Wegovy for CV risk reduction March 8, 2024 (SELECT trial), which opened Part D coverage for that use	FDA
Part D: Zepbound for sleep apnea	Covered (by indication)	FDA approved Zepbound for moderate-to-severe obstructive sleep apnea December 20, 2024 (SURMOUNT-OSA)	FDA
Part D: Wegovy for MASH	Covered (by indication)	FDA granted accelerated approval for noncirrhotic MASH with fibrosis in 2025 (ESSENCE trial)	FDA
Medicare GLP-1 Bridge (weight loss)	$50/mo copay	July 1, 2026–Dec 31, 2027. Eligibility: BMI ≥35; or ≥30 with heart failure, uncontrolled hypertension, or CKD; or ≥27 with prediabetes, prior MI, prior stroke, or PAD. The copay does not count toward the deductible or out-of-pocket cap	CMS
IRA-negotiated semaglutide price	~$274/mo	Takes effect January 1, 2027; a separate $245 most-favored-nation price also applies and how the two interact is unresolved	Fierce Pharma

Medicaid: coverage varies sharply by state

Medicaid coverage of GLP-1s for obesity is a patchwork that shrank in 2026. Diabetes coverage is near-universal across states, but weight-loss coverage is optional and several states dropped it. California's Medi-Cal ended weight-loss coverage at the start of the year, citing cost.

Channel	Price	Details	Source
States covering obesity GLP-1 (fee-for-service)	13 states	As of January 2026, down from 16 in October 2025; California, New Hampshire, Pennsylvania, and South Carolina dropped coverage	KFF
California Medi-Cal (weight loss)	Ended Jan 1, 2026	Wegovy, Zepbound, and Saxenda removed for members 21+; diabetes use still covered; the state cited a projected ~$800M/year cost	Medi-Cal Rx (DHCS)
Medicaid: diabetes indication	Covered	Ozempic, Mounjaro, and other GLP-1s remain covered for type 2 diabetes in essentially all states	KFF Health News
Patient cost in covering states	$0–$4	Nominal Medicaid prescription copays where obesity coverage applies	KFF

Cash pay and manufacturer savings programs

For the uninsured, the excluded, and the denied, both manufacturers run direct cash-pay channels and commercial savings cards. Cash prices fell sharply in late 2025. Savings cards cut copays for the commercially insured but exclude anyone on government insurance, and the diabetes-drug cards require a diabetes prescription.

Channel	Price	Details	Source
Wegovy self-pay (NovoCare Pharmacy)	$349/mo	Cut from $499 on November 17, 2025; a $199/month introductory price covers the first two fills of the two lowest doses	NovoCare Pharmacy
Wegovy oral tablet self-pay	$149/mo	1.5 mg and 4 mg at $149/month through August 31, 2026, then $199/month	NovoCare Pharmacy
Wegovy savings card (commercial coverage)	$0–$25/mo	Savings capped per fill; excludes Medicare, Medicaid, VA, DoD, and TRICARE	NovoCare
Zepbound self-pay vials (LillyDirect)	$299–$449/mo	$299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg with a 45-day refill); otherwise $499–$699 by dose	LillyDirect
Zepbound savings card (commercial coverage)	$25/mo	As little as $25 with Zepbound coverage; about $499/month without it; card expires Dec 31, 2026	Zepbound.com
Ozempic / Mounjaro savings cards (diabetes)	$25/mo	Require a type 2 diabetes prescription and commercial insurance; exclude Medicare, Medicaid, and other government programs	Ozempic.com

List prices and the 2026–2027 price-cut wave

List (WAC) prices are what uninsured patients face without a discount program, and what coverage decisions are negotiated against. They are falling: Novo Nordisk announced a steep list-price cut effective 2027, and the federal TrumpRx portal launched in February 2026 to route patients to manufacturer self-pay prices.

Channel	Price	Details	Source
Wegovy list (WAC)	~$1,349/mo	Before any discount, savings card, or cash-pay program	GoodRx
Zepbound list (WAC)	~$1,060/mo	Pen list price before discounts; self-pay vials are much lower	GoodRx
Ozempic / Mounjaro list (WAC)	~$998–$1,023/mo	Diabetes-indicated list prices before discounts	GoodRx
Novo Nordisk list-price cut	$675/mo	New list price for Wegovy, Ozempic, and Rybelsus effective January 1, 2027 (about 50% off Wegovy, 35% off Ozempic)	Novo Nordisk PR
TrumpRx portal	Launched Feb 5, 2026	Cash-only federal portal that links to manufacturer self-pay prices (Wegovy injection $199, Wegovy pill $149, Zepbound injection $299); it does not take insurance	CNBC

When you're denied: the appeals playbook

A prior-authorization denial is not the end of the road, and appeals succeed more often than most patients expect. Federal law gives commercially insured patients defined appeal rights and timelines, and independent reviewers overturn a large share of denials. The key is matching the response to the stated denial reason and supplying the documentation the plan asked for.

Channel	Price	Details	Source
Internal appeal window	180 days	Time to file after a denial; the insurer must decide within 30 days (before service) or 60 days (after)	KFF
External (independent) review	4 months to file	After internal appeals are exhausted; standard reviews finish within 45 days, urgent ones within 72 hours	KFF
External-review overturn rate	~47%	Share of external appeals decided in the consumer's favor in 2023	KFF
Step-therapy or formulary exception	Prescriber documentation	Document prior drugs tried with dates and side effects; a peer-to-peer review between prescriber and plan medical director often helps	Obesity Action Coalition
Self-insured plan appeal window	60 days	From the written denial (EOB); some states allow an external review up to 365 days after the final denial	Obesity Action Coalition